Suppressor of cell motility in ovarian carcinoma by modifying cell adhesion on the extracellular matrix; altered integrins (β1, α2, α3β1, α5, and α6) were found due to downregulation of CD9.Suppressor in fibrosarcoma by cell motility inhibition through CD9 complexes formed with TGFα, EGFR, EWI-2, EWIF, and β1.Promoter of cell motility in breast cancer by promoting α3β1 integrin. Here, CD9 is linked to breast carcinoma.